Clinical Trial Update: Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics and pharmacodynamics study of POSIPHEN in subjects with amnestic mild cognitive impairment and Alzheimer's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Amnestic Mild Cognitive Impairment

Drugs mentioned

• POSIPHEN (posiphen)

Snippet

Sponsor: Annovis Bio Inc. | Conditions: Alzheimer's Disease, Amnestic Mild Cognitive Impairment | Phase 1 | Status: TERMINATED